Handok's Non-Small Cell Lung Cancer Drug Development Project Selected for Ministry of Trade, Industry and Energy's Global Industry Technology Cooperation Center Program

  • 2024.09.09
  • 292
Handok's Non-Small Cell Lung Cancer Drug Development Project Selected for Ministry of Trade, Industry and Energy's Global Industry Technology Cooperation Center Program
 
Handok announced on the 9th that its non-small cell lung cancer drug development project has been selected for the Global Industry Technology Cooperation Center program, overseen by the Ministry of Trade, Industry and Energy.

The non-small cell lung cancer drug development project is led by Handok, with BNJ Biopharma and Massachusetts General Hospital (MGH) at Harvard Medical School in the United States as joint participants. This selection provides a total of 6 billion KRW in research funding over three years, with the possibility of an additional two years of funding based on research outcomes.

Handok plans to develop two new drugs in the field of non-small cell lung cancer, which has high unmet medical needs: a targeted protein degradation therapy and an antibody-drug conjugate targeted protein degradation therapy. Moon ByungGon, Director of Handok Central Research Institute, stated, "The epidermal growth factor receptor (EGFR), a major cause of non-small cell lung cancer, frequently mutates, limiting treatment options and creating high demand for new drugs. We will do our best to successfully develop advanced innovative drugs in collaboration with BNJ Biopharma and Harvard Medical School's MGH, which have excellent research capabilities, to lead the global market."

In April this year, Handok presented the research results of the new lung cancer treatment substance 'HDBNJ-2812' in a poster at the American Association for Cancer Research (AACR 2024). 'HDBNJ-2812', a compound secured through collaboration between Handok and BNJ Biopharma, showed effectiveness in degrading various EGFR mutant proteins and inhibiting cancer proliferation. It also demonstrated high drug stability and low cell toxicity potential, confirming its potential as a next-generation drug to overcome resistance to osimertinib.

Meanwhile, the Global Industry Technology Cooperation Center program aims to establish sustainable R&D cooperation models between Korean companies and leading global research institutions and to create excellent research outcomes with high industrial impact. The program supports fields such as semiconductors, batteries, biotechnology, future mobility, robotics, displays, AI, and emerging promising industries, including high-value-added advanced industries that will lead future industries.
 
List
맨위로